Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proctocolectomy, Restorative | 13 | 2020 | 17 | 1.890 |
Why?
|
| Inflammatory Bowel Diseases | 8 | 2020 | 29 | 1.060 |
Why?
|
| Crohn Disease | 5 | 2020 | 29 | 0.680 |
Why?
|
| Ileostomy | 6 | 2019 | 8 | 0.680 |
Why?
|
| Colitis, Ulcerative | 5 | 2019 | 24 | 0.620 |
Why?
|
| Colonic Pouches | 6 | 2018 | 9 | 0.540 |
Why?
|
| Genetic Counseling | 1 | 2017 | 8 | 0.530 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2017 | 4 | 0.530 |
Why?
|
| Pouchitis | 4 | 2018 | 4 | 0.500 |
Why?
|
| Fecal Incontinence | 2 | 2014 | 23 | 0.500 |
Why?
|
| Rectum | 1 | 2013 | 17 | 0.390 |
Why?
|
| Digital Rectal Examination | 1 | 2013 | 10 | 0.390 |
Why?
|
| Rectal Neoplasms | 1 | 2013 | 21 | 0.390 |
Why?
|
| Intestines | 1 | 2013 | 60 | 0.380 |
Why?
|
| Quality of Life | 6 | 2018 | 976 | 0.370 |
Why?
|
| Postoperative Complications | 6 | 2019 | 828 | 0.350 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 188 | 0.340 |
Why?
|
| Esophageal Atresia | 1 | 2011 | 1 | 0.340 |
Why?
|
| Esophagoplasty | 1 | 2011 | 1 | 0.340 |
Why?
|
| Esophageal Diseases | 1 | 2011 | 7 | 0.340 |
Why?
|
| Laparoscopy | 3 | 2018 | 184 | 0.320 |
Why?
|
| Follow-Up Studies | 10 | 2019 | 2287 | 0.290 |
Why?
|
| Humans | 29 | 2020 | 32968 | 0.270 |
Why?
|
| Sepsis | 4 | 2019 | 166 | 0.260 |
Why?
|
| Colectomy | 3 | 2017 | 30 | 0.250 |
Why?
|
| Clostridium Infections | 2 | 2018 | 10 | 0.250 |
Why?
|
| Female | 20 | 2020 | 20375 | 0.240 |
Why?
|
| Microcirculation | 3 | 2005 | 64 | 0.240 |
Why?
|
| Male | 22 | 2019 | 19754 | 0.240 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 74 | 0.240 |
Why?
|
| Liver | 2 | 2005 | 492 | 0.220 |
Why?
|
| Caveolins | 1 | 2004 | 2 | 0.220 |
Why?
|
| Endothelins | 1 | 2004 | 4 | 0.220 |
Why?
|
| Treatment Outcome | 8 | 2019 | 3460 | 0.220 |
Why?
|
| Adult | 15 | 2019 | 9586 | 0.220 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 34 | 0.220 |
Why?
|
| Middle Aged | 15 | 2019 | 12203 | 0.200 |
Why?
|
| Anastomosis, Surgical | 4 | 2017 | 57 | 0.190 |
Why?
|
| Colorectal Neoplasms | 2 | 2014 | 222 | 0.180 |
Why?
|
| Reoperation | 3 | 2019 | 260 | 0.180 |
Why?
|
| Intestinal Fistula | 1 | 2020 | 9 | 0.160 |
Why?
|
| Pelvic Infection | 1 | 2019 | 1 | 0.150 |
Why?
|
| Steroids | 1 | 2019 | 34 | 0.150 |
Why?
|
| Clostridium difficile | 2 | 2018 | 12 | 0.150 |
Why?
|
| Dilatation | 1 | 2018 | 8 | 0.140 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2018 | 23 | 0.140 |
Why?
|
| Constriction, Pathologic | 1 | 2018 | 47 | 0.140 |
Why?
|
| Intestinal Diseases | 1 | 2018 | 16 | 0.140 |
Why?
|
| Colitis | 1 | 2017 | 7 | 0.140 |
Why?
|
| Retrospective Studies | 8 | 2019 | 3708 | 0.130 |
Why?
|
| Gastrointestinal Agents | 1 | 2017 | 6 | 0.130 |
Why?
|
| Abdomen | 1 | 2017 | 46 | 0.130 |
Why?
|
| Genetic Testing | 1 | 2017 | 99 | 0.130 |
Why?
|
| Young Adult | 6 | 2019 | 2738 | 0.120 |
Why?
|
| Endothelin-1 | 3 | 2005 | 18 | 0.120 |
Why?
|
| Time Factors | 3 | 2015 | 2195 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 332 | 0.110 |
Why?
|
| Prognosis | 5 | 2019 | 1547 | 0.110 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2015 | 4 | 0.110 |
Why?
|
| Registries | 2 | 2014 | 320 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2019 | 880 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2018 | 351 | 0.110 |
Why?
|
| Gastrostomy | 1 | 2015 | 16 | 0.110 |
Why?
|
| Splenic Diseases | 1 | 2014 | 4 | 0.110 |
Why?
|
| Endoscopy | 1 | 2015 | 56 | 0.110 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2014 | 47 | 0.110 |
Why?
|
| Pancreas | 1 | 2015 | 103 | 0.110 |
Why?
|
| Liver Circulation | 2 | 2005 | 7 | 0.110 |
Why?
|
| Inflammation | 1 | 2017 | 542 | 0.110 |
Why?
|
| Spleen | 1 | 2014 | 85 | 0.100 |
Why?
|
| Intraoperative Complications | 1 | 2014 | 59 | 0.100 |
Why?
|
| Risk Factors | 6 | 2018 | 4001 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 158 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 476 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2019 | 2338 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 1310 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 300 | 0.090 |
Why?
|
| Adolescent | 5 | 2019 | 3643 | 0.090 |
Why?
|
| Aged | 7 | 2018 | 10637 | 0.090 |
Why?
|
| Logistic Models | 3 | 2018 | 783 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 682 | 0.090 |
Why?
|
| Esophageal Stenosis | 1 | 2011 | 6 | 0.090 |
Why?
|
| Stomach | 1 | 2011 | 17 | 0.080 |
Why?
|
| Esophagus | 1 | 2011 | 25 | 0.080 |
Why?
|
| Gastrectomy | 1 | 2011 | 70 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 599 | 0.080 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2011 | 198 | 0.070 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2009 | 71 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 780 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2009 | 114 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2005 | 754 | 0.070 |
Why?
|
| Melanoma | 1 | 2009 | 165 | 0.070 |
Why?
|
| Ohio | 2 | 2018 | 64 | 0.070 |
Why?
|
| Perfusion | 2 | 2004 | 74 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2019 | 156 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 217 | 0.060 |
Why?
|
| Rats | 3 | 2005 | 1610 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2004 | 500 | 0.060 |
Why?
|
| Kupffer Cells | 1 | 2005 | 10 | 0.060 |
Why?
|
| Length of Stay | 2 | 2018 | 329 | 0.060 |
Why?
|
| Calmodulin | 1 | 2004 | 2 | 0.050 |
Why?
|
| Fractures, Closed | 1 | 2004 | 9 | 0.050 |
Why?
|
| Microscopy, Video | 1 | 2004 | 7 | 0.050 |
Why?
|
| Immunoprecipitation | 1 | 2004 | 32 | 0.050 |
Why?
|
| Caveolin 1 | 1 | 2004 | 13 | 0.050 |
Why?
|
| Femoral Fractures | 1 | 2005 | 45 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2004 | 35 | 0.050 |
Why?
|
| Catalysis | 1 | 2004 | 66 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 91 | 0.050 |
Why?
|
| Blood Flow Velocity | 1 | 2004 | 77 | 0.050 |
Why?
|
| Protein Binding | 1 | 2004 | 201 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 255 | 0.050 |
Why?
|
| RNA | 1 | 2004 | 87 | 0.050 |
Why?
|
| Disease Management | 2 | 2014 | 128 | 0.050 |
Why?
|
| Peptides | 1 | 2004 | 126 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2004 | 290 | 0.050 |
Why?
|
| Wounds and Injuries | 1 | 2004 | 245 | 0.040 |
Why?
|
| Incidence | 2 | 2015 | 1246 | 0.040 |
Why?
|
| Florida | 1 | 2020 | 38 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2020 | 42 | 0.040 |
Why?
|
| Defecation | 1 | 2018 | 6 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 189 | 0.040 |
Why?
|
| Animals | 3 | 2005 | 7599 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 2019 | 98 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 43 | 0.030 |
Why?
|
| Brachytherapy | 1 | 2017 | 24 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 4065 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2017 | 83 | 0.030 |
Why?
|
| Demography | 1 | 2017 | 110 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 2017 | 14 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 78 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 213 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 256 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2015 | 45 | 0.030 |
Why?
|
| Drainage | 1 | 2015 | 64 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 205 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 194 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2015 | 413 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 282 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 684 | 0.030 |
Why?
|
| Survival Rate | 1 | 2014 | 895 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 950 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2009 | 95 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 169 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 384 | 0.020 |
Why?
|
| United States | 1 | 2014 | 4132 | 0.010 |
Why?
|
| Ferrous Compounds | 1 | 2005 | 6 | 0.010 |
Why?
|
| Cecum | 1 | 2005 | 10 | 0.010 |
Why?
|
| NAD | 1 | 2005 | 27 | 0.010 |
Why?
|
| Ligation | 1 | 2005 | 60 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 1469 | 0.010 |
Why?
|
| Receptor, Endothelin A | 1 | 2002 | 4 | 0.010 |
Why?
|
| Receptor, Endothelin B | 1 | 2002 | 5 | 0.010 |
Why?
|
| Receptors, Endothelin | 1 | 2002 | 4 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 2002 | 46 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2002 | 111 | 0.010 |
Why?
|